文献速递淋巴瘤白血病

泽布替尼联合奥妥珠单抗治疗慢性淋巴细胞白血病和滤泡性淋巴瘤的1期研究

Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

这项1期研究评估了泽布替尼联合奥妥珠单抗在81例CLL/SLL或复发/难治FL患者中的安全性和早期疗效。泽布替尼160 mg每日两次或320 mg每日一次联合静脉奥妥珠单抗可耐受,常见不良事件包括上呼吸道感染和中性粒细胞减少。初治CLL的ORR为100%,R/R CLL为92%,R/R FL为72%。

要点

  • 泽布替尼联合奥妥珠单抗在CLL/SLL和FL患者中总体耐受良好。
  • 初治CLL的ORR达100%,R/R CLL为92%,R/R FL为72%。
  • 中性粒细胞减少是最常见的3/4级不良事件。

核心结论

  • 泽布替尼联合奥妥珠单抗治疗CLL/SLL和R/R FL总体耐受良好,并显示出早期疗效。

研究设计与样本

  • 1期研究纳入81例CLL/SLL或R/R FL患者,评估泽布替尼联合奥妥珠单抗的安全性及早期疗效。

主要发现

  • CLL/SLL患者常见不良事件包括上呼吸道感染51%(n=23)、中性粒细胞减少44%(n=20)、瘀伤33%(n=15)。
  • FL患者常见不良事件包括上呼吸道感染39%(n=14)、瘀伤28%(n=10)、乏力25%(n=9)。
  • 中性粒细胞减少是最常见的3/4级不良事件,CLL/SLL为31%(n=14),FL为14%(n=5)。
  • 初治CLL的ORR为100%(n=20),R/R CLL为92%(n=23),R/R FL为72%(n=26)。
  • CLL患者中位随访29个月(范围8-37),FL患者中位随访20个月(范围2-37)。

关键数值与推荐

  • 泽布替尼160 mg每日两次或320 mg每日一次联合静脉奥妥珠单抗可耐受。
  • 5例患者需暂时减量,5例因不良事件停药。

临床怎么用

  • 该联合方案可作为CLL/SLL和R/R FL患者的潜在治疗选择,但需监测中性粒细胞减少等不良事件。

局限性

  • 本研究为1期研究,样本量有限,疗效需进一步随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Zanubrutinib (BGB-3111) is a next-generation Bruton tyrosine kinase inhibitor designed to be more selective with fewer off-target effects. We conducted a phase 1 study to assess the safety of its combination with obinutuzumab and evaluate early efficacy in 81 patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or relapsed/refractory (R/R) follicular lymphoma (FL). In this phase 1b study, zanubrutinib was tolerable at 160 mg twice daily or 320 mg once daily combined with IV obinutuzumab in patients with CLL/SLL (n = 45) and FL (n = 36). Common adverse events (AEs) included upper respiratory tract infection (51%; n = 23), neutropenia (44%; n = 20), contusion (33%; n = 15), cough, diarrhea, or fatigue (27%; n = 12 each), and pyrexia (22%; n = 10) in CLL/SLL patients and upper respiratory tract infection (39%; n = 14), contusion (28%; n = 10), fatigue (25%; n = 9), and cough (22%; n = 8) in FL patients. Neutropenia was the most common grade 3/4 AE (CLL/SLL, 31% [n = 14]; FL, 14% [n = 5]). Five patients required temporary dose reductions, and 5 discontinued the study drug because of AEs. Overall response rate (ORR) was 100% (n = 20) in treatment-naïve CLL patients and 92% (n = 23) in R/R CLL patients. ORR in 36 R/R FL patients was 72% (n = 26), with 14 complete and 12 partial responses. Median follow-up was 29 months (range, 8-37) for CLL patients and 20 months (range, 2-37) for FL patients. Zanubrutinib and obinutuzumab combination therapy was generally well tolerated. This trial was registered at www.clinicaltrials.gov as #NCT02569476.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tam CS, Quach H, Nicol A, et al. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. Blood Adv. 2020. PMID: 33022066. doi:10.1182/bloodadvances.2020002183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。